Anti-Hypertensive Drugs - Worldwide

  • Worldwide
  • The Anti-Hypertensive Drugs market worldwide is expected to achieve a revenue of US$22.48bn by the year 2024.
  • It is anticipated that the revenue will grow annually at a rate of -0.25% (CAGR 2024-2028), leading to a market volume of US$22.26bn by 2028.
  • In terms of global comparison, United States is projected to generate the highest revenue of US$12,290.00m in 2024.
  • The demand for anti-hypertensive drugs is rising worldwide as countries prioritize healthcare and manage the increasing prevalence of hypertension.

Key regions: Germany, United States, France, China, Canada

Region comparison

Analyst Opinion

The demand for Anti-Hypertensive Drugs has been steadily increasing in recent years due to the growing prevalence of hypertension worldwide.

Customer preferences:
Patients suffering from hypertension prefer drugs that are effective in managing their blood pressure levels while having minimal side effects. They also prefer drugs that are affordable and easily accessible.

Trends in the market:
In the United States, the Anti-Hypertensive Drugs market has been driven by the increasing number of people diagnosed with hypertension, which is estimated to affect one in every three adults. The market is dominated by generic drugs due to their affordability. However, there is a growing demand for branded drugs that offer better efficacy and fewer side effects. In Europe, the market is also dominated by generic drugs due to the cost-containment measures implemented by governments and health insurance providers. However, there is a growing trend towards the use of combination therapies that offer better efficacy in managing hypertension. In Asia, the market is driven by the increasing prevalence of hypertension, particularly in China and India. There is a growing demand for both generic and branded drugs, with a preference for drugs that are affordable and easily accessible.

Local special circumstances:
In Brazil, the Anti-Hypertensive Drugs market is heavily regulated, with strict price controls and a preference for locally manufactured drugs. This has led to a limited number of international players in the market. In Japan, the market is dominated by domestic players who have developed innovative drugs that are highly effective in managing hypertension.

Underlying macroeconomic factors:
The global Anti-Hypertensive Drugs market is expected to continue growing due to the increasing prevalence of hypertension worldwide. The market is also driven by the aging population and the growing adoption of unhealthy lifestyles, such as a sedentary lifestyle and unhealthy diets. However, the market is also facing challenges such as the increasing cost of drug development and the growing competition from generic drugs. Governments and health insurance providers are also implementing cost-containment measures that are affecting the profitability of drug manufacturers. In conclusion, the Anti-Hypertensive Drugs market is expected to continue growing due to the increasing prevalence of hypertension worldwide. However, drug manufacturers need to focus on developing innovative drugs that offer better efficacy and fewer side effects to remain competitive in the market. They also need to address the challenges posed by cost-containment measures and the growing competition from generic drugs.


Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.


In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.


  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait


Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)